The Israeli pharmaceutical company is working with advisors to gauge interest on such a sale, “Bloomberg” reports. Teva Pharmaceutical Industries Ltd. (NYSE: TEVA ; TASE: TEVA ) is considering the sale of its active pharmaceutical (API) ingredients production activities in a deal that could reach $2 billion, “Bloomberg” reports. The…Read More
Teva mulls 2b sale of API activities report
